Ligand Pharma partner wins Chinese approval for anti-PD-1; Brickell receives exclusive rights to DYRK1A inhibitor

California biopharma company Ligand Pharmaceuticals announced today that partner Gloria Biosciences has received a new approval from China’s National Medical Products Administration.

This approval is for the anti-PD-1 antibody zimberelimab for treating recurrent or refractory classical Hodgkin’s lymphoma. Gloria Bio has development and commercialization rights in...

Click to view original post